Self-funded Employers Control MSK Healthcare Costs With the Regenexx Corporate Program

The Regenexx Corporate Program is a proactive, fiscally responsible solution that moves beyond status quo treatments to deliver deeper musculoskeletal cost savings. Informed by over 20 years of patient data and research, the Regenexx approach provides a less invasive alternative to traditional orthopedic surgeries that helps the body do what it does naturally with use of the patient’s own cells.

Our program delivers a high-value option for employers seeking a compliant, cost-saving option that passes the test for experimental and investigative procedures through key criteria including: safety, efficacy, and net clinical benefit. Our team supports employers and members every step of the way from implementation and utilization to benefit education and more.

Learn more

Regenexx Corporate Program Overview

Time For a Second Opinion on Your MSK Spend?

If spending on musculoskeletal conditions – including back, joint, and soft tissue disorders – is consistently one of the top three healthcare cost drivers it’s time to take a closer look. For many large employer groups, MSK spend ranks first or second among all Major Diagnostic Categories (MDCs), often accounting for 15-20% of other total medical spend. The Regenexx Corporate Program regularly helps partners achieve MSK spend cuts by 50% or more — which often contributes to a reduction in total medical spend by up to 10%.

Your MSK spend deserves a closer look from our team of experts who can help you evaluate the key areas driving your cost and provide you with a second opinion on your current strategy. Request your complimentary, comprehensive impact study that demonstrates your potential for MSK cost savings using your own deidentified data.

Request an Impact Study

What’s Driving The Cost?

Proven Value for Employers, Groups, and Members

MSK care solutions that reduce unnecessary procedures, optimize care pathways, and proactively engage employees yield significant mutual benefit for organizations and their personnel. Discover the impact a partnership with the Regenexx Corporate Program has for our members and learn more about what they value and why they chose the Regenexx benefit.

Health Plan Value

Save up to 70% compared to surgical options
Reduce absenteeism
Reduce opioid medications
Activity as tolerated recovery

Member Benefit

An innovative option in MSK care
Increased affordability
Low-risk treatments – injection based vs. surgery
Access to leading specialist physicians

Easy to Add and Implement

No cost to add or implement
Can be implemented at any time – no need to wait for plan renewal
Turnkey member communication drive awareness and engagement
Utilization program based on member education

Unlocking Deeper MSK Cost Savings Through Strategic Intervention and Utilization Review

Utilization review is a standard part of the Regenexx Corporate Program. We start with two fundamental questions:

Is the procedure using Regenexx injectates appropriate for the patient?
Is there a cost-savings opportunity compared to the surgical alternative?

Every procedure using Regenexx injectates must be reviewed and approved to ensure physicians in the licensed Regenexx network deliver high-value services to members and that conservative care is the first step. Physicians may recommend physical therapy or a low-dose steroid injection prior to being considered a candidate for a procedure using Regenexx injectates unless their condition has already failed to respond to conservative care. The utilization review process for benefit member care is founded in the clinical integrity and outcomes data of the Regenexx approach to candidacy.

Our team understands that to accurately calculate savings, it is essential to consider how often various procedures to treat orthopedic issues fail and lead to surgery. Utilization review helps further ensure that patients with good candidacy ratings move forward with appropriate physician recommended care and supports cost savings by reducing unnecessary or inappropriate treatments. To understand more details of how candidacy is determined and how outcomes support utilization, watch these short videos from Regenexx founder Dr. Chris Centeno.

Regenexx ACL Stem Cell Procedure Candidacy Tool

Regenexx Network Outcome Reporting Tool

Regenexx Clears the Bar—So You Can Clear the Doubts

The Regenexx benefit can be confidently added to a self-funded health plan because the Regenexx approach to MSK care and its proprietary methods and injectates are uniquely positioned to meet the five key criteria insurers use to evaluate investigational treatments—including:

Safety: Largest published safety dataset in orthobiologics
Efficacy: Peer-reviewed RCTs on PRP (platelet rich plasma) and BMC (bone marrow concentrate which contains stem cells)
Regulatory Pathway: Regenexx is compliant with FDA’s 21 CFR 1271.15(b)
Comparable to Standard of Care: Often equal or superior to orthopedic surgery
Prevalence: In use outside clinical trials since 2005

Unlike providers in the unregulated “stem cell” space or those offering typical PRP procedures, the Regenexx approach applies strict clinical and operational controls including: physician credentialing, training to prepare the injectate and customize the dose, biologic standardization, outcomes tracking, and real-time utilization review.

For self-funded plans, this makes Regenexx a low-risk, high-value addition that is proven to reduce costs and improve employee outcomes—while still aligning with the investigational coverage policies of major TPAs.